nodes	percent_of_prediction	percent_of_DWPC	metapath
Lovastatin—UGT2B7—Epirubicin—thyroid cancer	0.159	0.214	CbGbCtD
Lovastatin—UGT1A1—Sorafenib—thyroid cancer	0.121	0.162	CbGbCtD
Lovastatin—ABCC2—Sorafenib—thyroid cancer	0.0733	0.0987	CbGbCtD
Lovastatin—CYP3A7—Sorafenib—thyroid cancer	0.049	0.0659	CbGbCtD
Lovastatin—CYP3A7-CYP3A51P—Sorafenib—thyroid cancer	0.049	0.0659	CbGbCtD
Lovastatin—ABCC2—Doxorubicin—thyroid cancer	0.0445	0.0599	CbGbCtD
Lovastatin—CYP3A5—Sorafenib—thyroid cancer	0.0367	0.0494	CbGbCtD
Lovastatin—CYP2C8—Sorafenib—thyroid cancer	0.0353	0.0475	CbGbCtD
Lovastatin—CYP2C19—Sorafenib—thyroid cancer	0.0296	0.0399	CbGbCtD
Lovastatin—CYP2C9—Sorafenib—thyroid cancer	0.0246	0.0331	CbGbCtD
Lovastatin—ABCB1—Sorafenib—thyroid cancer	0.0239	0.0322	CbGbCtD
Lovastatin—CYP3A4—Vandetanib—thyroid cancer	0.0238	0.032	CbGbCtD
Lovastatin—CYP2D6—Sorafenib—thyroid cancer	0.0225	0.0303	CbGbCtD
Lovastatin—ABCB1—Doxorubicin—thyroid cancer	0.0145	0.0195	CbGbCtD
Lovastatin—CYP3A4—Sorafenib—thyroid cancer	0.0143	0.0193	CbGbCtD
Lovastatin—CYP2D6—Doxorubicin—thyroid cancer	0.0137	0.0184	CbGbCtD
Lovastatin—HDAC2—parathyroid gland—thyroid cancer	0.0102	0.193	CbGeAlD
Lovastatin—Hepatocellular carcinoma—Sorafenib—thyroid cancer	0.0096	0.0731	CcSEcCtD
Lovastatin—Hepatic cancer—Sorafenib—thyroid cancer	0.00874	0.0665	CcSEcCtD
Lovastatin—CYP3A4—Doxorubicin—thyroid cancer	0.00869	0.0117	CbGbCtD
Lovastatin—PON3—saliva-secreting gland—thyroid cancer	0.00591	0.112	CbGeAlD
Lovastatin—ITGAL—trachea—thyroid cancer	0.00465	0.0882	CbGeAlD
Lovastatin—ITGAL—thyroid gland—thyroid cancer	0.00368	0.0698	CbGeAlD
Lovastatin—PON3—thyroid gland—thyroid cancer	0.0036	0.0684	CbGeAlD
Lovastatin—HDAC2—Afatinib—Vandetanib—thyroid cancer	0.00344	0.534	CbGdCrCtD
Lovastatin—HDAC2—neck—thyroid cancer	0.00309	0.0586	CbGeAlD
Lovastatin—HDAC2—Gefitinib—Vandetanib—thyroid cancer	0.00301	0.466	CbGdCrCtD
Lovastatin—HMGCR—neck—thyroid cancer	0.00279	0.0529	CbGeAlD
Lovastatin—Cataract—Vandetanib—thyroid cancer	0.00273	0.0208	CcSEcCtD
Lovastatin—HDAC2—saliva-secreting gland—thyroid cancer	0.00241	0.0457	CbGeAlD
Lovastatin—ITGAL—lymph node—thyroid cancer	0.00228	0.0433	CbGeAlD
Lovastatin—HMGCR—saliva-secreting gland—thyroid cancer	0.00217	0.0412	CbGeAlD
Lovastatin—Rhabdomyolysis—Sorafenib—thyroid cancer	0.00198	0.0151	CcSEcCtD
Lovastatin—HMGCR—trachea—thyroid cancer	0.00168	0.0318	CbGeAlD
Lovastatin—Influenza—Vandetanib—thyroid cancer	0.00163	0.0124	CcSEcCtD
Lovastatin—Pancreatitis—Vandetanib—thyroid cancer	0.0016	0.0122	CcSEcCtD
Lovastatin—Gynaecomastia—Sorafenib—thyroid cancer	0.00157	0.0119	CcSEcCtD
Lovastatin—Photosensitivity reaction—Vandetanib—thyroid cancer	0.00149	0.0113	CcSEcCtD
Lovastatin—HDAC2—thyroid gland—thyroid cancer	0.00147	0.0279	CbGeAlD
Lovastatin—Hepatic function abnormal—Sorafenib—thyroid cancer	0.00146	0.0111	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Vandetanib—thyroid cancer	0.00144	0.011	CcSEcCtD
Lovastatin—Hepatic failure—Sorafenib—thyroid cancer	0.00142	0.0108	CcSEcCtD
Lovastatin—Urinary tract infection—Vandetanib—thyroid cancer	0.00141	0.0108	CcSEcCtD
Lovastatin—Sinusitis—Vandetanib—thyroid cancer	0.00136	0.0104	CcSEcCtD
Lovastatin—HMGCR—thyroid gland—thyroid cancer	0.00133	0.0252	CbGeAlD
Lovastatin—HDAC2—head—thyroid cancer	0.0013	0.0247	CbGeAlD
Lovastatin—Pain in extremity—Sorafenib—thyroid cancer	0.00127	0.00969	CcSEcCtD
Lovastatin—Erythema multiforme—Vandetanib—thyroid cancer	0.00123	0.0094	CcSEcCtD
Lovastatin—HMGCR—head—thyroid cancer	0.00118	0.0223	CbGeAlD
Lovastatin—Alopecia—Vandetanib—thyroid cancer	0.00115	0.00878	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00115	0.00873	CcSEcCtD
Lovastatin—Dysgeusia—Vandetanib—thyroid cancer	0.00111	0.00847	CcSEcCtD
Lovastatin—Muscle spasms—Vandetanib—thyroid cancer	0.00109	0.00832	CcSEcCtD
Lovastatin—Pancreatitis—Sorafenib—thyroid cancer	0.00108	0.00821	CcSEcCtD
Lovastatin—Vision blurred—Vandetanib—thyroid cancer	0.00107	0.00816	CcSEcCtD
Lovastatin—Transaminases increased—Epirubicin—thyroid cancer	0.00107	0.00811	CcSEcCtD
Lovastatin—Tremor—Vandetanib—thyroid cancer	0.00106	0.00811	CcSEcCtD
Lovastatin—Abdominal discomfort—Sorafenib—thyroid cancer	0.00105	0.00803	CcSEcCtD
Lovastatin—Erectile dysfunction—Sorafenib—thyroid cancer	0.00101	0.00772	CcSEcCtD
Lovastatin—Transaminases increased—Doxorubicin—thyroid cancer	0.000986	0.00751	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.000973	0.00741	CcSEcCtD
Lovastatin—Arthralgia—Vandetanib—thyroid cancer	0.000968	0.00737	CcSEcCtD
Lovastatin—Chest pain—Vandetanib—thyroid cancer	0.000968	0.00737	CcSEcCtD
Lovastatin—Anxiety—Vandetanib—thyroid cancer	0.000964	0.00734	CcSEcCtD
Lovastatin—Neuropathy peripheral—Sorafenib—thyroid cancer	0.000962	0.00732	CcSEcCtD
Lovastatin—Dry mouth—Vandetanib—thyroid cancer	0.000946	0.0072	CcSEcCtD
Lovastatin—Infection—Vandetanib—thyroid cancer	0.000922	0.00702	CcSEcCtD
Lovastatin—SLCO1A2—head—thyroid cancer	0.000917	0.0174	CbGeAlD
Lovastatin—HDAC2—lymph node—thyroid cancer	0.000913	0.0173	CbGeAlD
Lovastatin—Thrombocytopenia—Vandetanib—thyroid cancer	0.000908	0.00691	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000845	0.00643	CcSEcCtD
Lovastatin—Insomnia—Vandetanib—thyroid cancer	0.000839	0.00639	CcSEcCtD
Lovastatin—Paraesthesia—Vandetanib—thyroid cancer	0.000833	0.00634	CcSEcCtD
Lovastatin—Erythema multiforme—Sorafenib—thyroid cancer	0.000833	0.00634	CcSEcCtD
Lovastatin—Dyspnoea—Vandetanib—thyroid cancer	0.000827	0.0063	CcSEcCtD
Lovastatin—HMGCR—lymph node—thyroid cancer	0.000823	0.0156	CbGeAlD
Lovastatin—Flushing—Sorafenib—thyroid cancer	0.000817	0.00622	CcSEcCtD
Lovastatin—Dyspepsia—Vandetanib—thyroid cancer	0.000817	0.00622	CcSEcCtD
Lovastatin—Decreased appetite—Vandetanib—thyroid cancer	0.000806	0.00614	CcSEcCtD
Lovastatin—Fatigue—Vandetanib—thyroid cancer	0.0008	0.00609	CcSEcCtD
Lovastatin—Pain—Vandetanib—thyroid cancer	0.000793	0.00604	CcSEcCtD
Lovastatin—Constipation—Vandetanib—thyroid cancer	0.000793	0.00604	CcSEcCtD
Lovastatin—Alopecia—Sorafenib—thyroid cancer	0.000778	0.00593	CcSEcCtD
Lovastatin—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000759	0.00577	CcSEcCtD
Lovastatin—Dysgeusia—Sorafenib—thyroid cancer	0.000751	0.00572	CcSEcCtD
Lovastatin—Jaundice cholestatic—Epirubicin—thyroid cancer	0.000738	0.00562	CcSEcCtD
Lovastatin—Muscle spasms—Sorafenib—thyroid cancer	0.000737	0.00561	CcSEcCtD
Lovastatin—Body temperature increased—Vandetanib—thyroid cancer	0.000733	0.00558	CcSEcCtD
Lovastatin—Abdominal pain—Vandetanib—thyroid cancer	0.000733	0.00558	CcSEcCtD
Lovastatin—Angioedema—Sorafenib—thyroid cancer	0.000701	0.00533	CcSEcCtD
Lovastatin—Leukopenia—Sorafenib—thyroid cancer	0.000686	0.00522	CcSEcCtD
Lovastatin—Jaundice cholestatic—Doxorubicin—thyroid cancer	0.000683	0.0052	CcSEcCtD
Lovastatin—Asthenia—Vandetanib—thyroid cancer	0.000666	0.00507	CcSEcCtD
Lovastatin—Pruritus—Vandetanib—thyroid cancer	0.000656	0.005	CcSEcCtD
Lovastatin—Musculoskeletal pain—Epirubicin—thyroid cancer	0.000656	0.00499	CcSEcCtD
Lovastatin—Arthralgia—Sorafenib—thyroid cancer	0.000653	0.00497	CcSEcCtD
Lovastatin—Myalgia—Sorafenib—thyroid cancer	0.000653	0.00497	CcSEcCtD
Lovastatin—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.000648	0.00493	CcSEcCtD
Lovastatin—Dry mouth—Sorafenib—thyroid cancer	0.000638	0.00486	CcSEcCtD
Lovastatin—Diarrhoea—Vandetanib—thyroid cancer	0.000635	0.00483	CcSEcCtD
Lovastatin—Anaphylactic shock—Sorafenib—thyroid cancer	0.000626	0.00476	CcSEcCtD
Lovastatin—Infection—Sorafenib—thyroid cancer	0.000622	0.00473	CcSEcCtD
Lovastatin—Dizziness—Vandetanib—thyroid cancer	0.000613	0.00467	CcSEcCtD
Lovastatin—Thrombocytopenia—Sorafenib—thyroid cancer	0.000613	0.00466	CcSEcCtD
Lovastatin—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.000607	0.00462	CcSEcCtD
Lovastatin—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.0006	0.00457	CcSEcCtD
Lovastatin—ABCC2—lymph node—thyroid cancer	0.000598	0.0114	CbGeAlD
Lovastatin—Anorexia—Sorafenib—thyroid cancer	0.000596	0.00454	CcSEcCtD
Lovastatin—Vomiting—Vandetanib—thyroid cancer	0.00059	0.00449	CcSEcCtD
Lovastatin—Rash—Vandetanib—thyroid cancer	0.000585	0.00445	CcSEcCtD
Lovastatin—Dermatitis—Vandetanib—thyroid cancer	0.000584	0.00445	CcSEcCtD
Lovastatin—Headache—Vandetanib—thyroid cancer	0.000581	0.00442	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00057	0.00434	CcSEcCtD
Lovastatin—Dyspnoea—Sorafenib—thyroid cancer	0.000558	0.00425	CcSEcCtD
Lovastatin—Nausea—Vandetanib—thyroid cancer	0.000551	0.00419	CcSEcCtD
Lovastatin—Dyspepsia—Sorafenib—thyroid cancer	0.000551	0.00419	CcSEcCtD
Lovastatin—Decreased appetite—Sorafenib—thyroid cancer	0.000544	0.00414	CcSEcCtD
Lovastatin—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.000541	0.00412	CcSEcCtD
Lovastatin—Fatigue—Sorafenib—thyroid cancer	0.000539	0.00411	CcSEcCtD
Lovastatin—Hepatic function abnormal—Epirubicin—thyroid cancer	0.000538	0.0041	CcSEcCtD
Lovastatin—Photosensitivity—Epirubicin—thyroid cancer	0.000536	0.00408	CcSEcCtD
Lovastatin—Pain—Sorafenib—thyroid cancer	0.000535	0.00407	CcSEcCtD
Lovastatin—Constipation—Sorafenib—thyroid cancer	0.000535	0.00407	CcSEcCtD
Lovastatin—Vascular purpura—Epirubicin—thyroid cancer	0.000526	0.004	CcSEcCtD
Lovastatin—Hepatic failure—Epirubicin—thyroid cancer	0.000524	0.00399	CcSEcCtD
Lovastatin—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000512	0.0039	CcSEcCtD
Lovastatin—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000501	0.00381	CcSEcCtD
Lovastatin—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000498	0.00379	CcSEcCtD
Lovastatin—Urticaria—Sorafenib—thyroid cancer	0.000497	0.00378	CcSEcCtD
Lovastatin—Photosensitivity—Doxorubicin—thyroid cancer	0.000496	0.00377	CcSEcCtD
Lovastatin—Abdominal pain—Sorafenib—thyroid cancer	0.000495	0.00377	CcSEcCtD
Lovastatin—Body temperature increased—Sorafenib—thyroid cancer	0.000495	0.00377	CcSEcCtD
Lovastatin—Purpura—Epirubicin—thyroid cancer	0.000488	0.00372	CcSEcCtD
Lovastatin—Vascular purpura—Doxorubicin—thyroid cancer	0.000487	0.00371	CcSEcCtD
Lovastatin—Hepatic failure—Doxorubicin—thyroid cancer	0.000484	0.00369	CcSEcCtD
Lovastatin—Pain in extremity—Epirubicin—thyroid cancer	0.000471	0.00358	CcSEcCtD
Lovastatin—Hypersensitivity—Sorafenib—thyroid cancer	0.000461	0.00351	CcSEcCtD
Lovastatin—Purpura—Doxorubicin—thyroid cancer	0.000452	0.00344	CcSEcCtD
Lovastatin—Asthenia—Sorafenib—thyroid cancer	0.000449	0.00342	CcSEcCtD
Lovastatin—Pruritus—Sorafenib—thyroid cancer	0.000443	0.00337	CcSEcCtD
Lovastatin—ABCB1—trachea—thyroid cancer	0.000438	0.00831	CbGeAlD
Lovastatin—Pain in extremity—Doxorubicin—thyroid cancer	0.000435	0.00331	CcSEcCtD
Lovastatin—Diarrhoea—Sorafenib—thyroid cancer	0.000428	0.00326	CcSEcCtD
Lovastatin—CYP2D6—head—thyroid cancer	0.000427	0.00811	CbGeAlD
Lovastatin—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000424	0.00323	CcSEcCtD
Lovastatin—Dizziness—Sorafenib—thyroid cancer	0.000414	0.00315	CcSEcCtD
Lovastatin—Influenza—Epirubicin—thyroid cancer	0.000407	0.0031	CcSEcCtD
Lovastatin—Eosinophilia—Epirubicin—thyroid cancer	0.000403	0.00307	CcSEcCtD
Lovastatin—Pancreatitis—Epirubicin—thyroid cancer	0.000399	0.00304	CcSEcCtD
Lovastatin—Vomiting—Sorafenib—thyroid cancer	0.000398	0.00303	CcSEcCtD
Lovastatin—Rash—Sorafenib—thyroid cancer	0.000395	0.003	CcSEcCtD
Lovastatin—Dermatitis—Sorafenib—thyroid cancer	0.000394	0.003	CcSEcCtD
Lovastatin—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000392	0.00298	CcSEcCtD
Lovastatin—Headache—Sorafenib—thyroid cancer	0.000392	0.00298	CcSEcCtD
Lovastatin—Influenza—Doxorubicin—thyroid cancer	0.000376	0.00286	CcSEcCtD
Lovastatin—Eosinophilia—Doxorubicin—thyroid cancer	0.000373	0.00284	CcSEcCtD
Lovastatin—Nausea—Sorafenib—thyroid cancer	0.000372	0.00283	CcSEcCtD
Lovastatin—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000371	0.00283	CcSEcCtD
Lovastatin—Pancreatitis—Doxorubicin—thyroid cancer	0.000369	0.00281	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000359	0.00274	CcSEcCtD
Lovastatin—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000355	0.00271	CcSEcCtD
Lovastatin—Urinary tract infection—Epirubicin—thyroid cancer	0.000352	0.00268	CcSEcCtD
Lovastatin—ABCB1—thyroid gland—thyroid cancer	0.000346	0.00657	CbGeAlD
Lovastatin—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000343	0.00261	CcSEcCtD
Lovastatin—Sinusitis—Epirubicin—thyroid cancer	0.00034	0.00259	CcSEcCtD
Lovastatin—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000333	0.00253	CcSEcCtD
Lovastatin—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000329	0.0025	CcSEcCtD
Lovastatin—Urinary tract infection—Doxorubicin—thyroid cancer	0.000326	0.00248	CcSEcCtD
Lovastatin—Hepatitis—Epirubicin—thyroid cancer	0.000326	0.00248	CcSEcCtD
Lovastatin—Sinusitis—Doxorubicin—thyroid cancer	0.000315	0.0024	CcSEcCtD
Lovastatin—Erythema multiforme—Epirubicin—thyroid cancer	0.000308	0.00234	CcSEcCtD
Lovastatin—ABCB1—head—thyroid cancer	0.000307	0.00583	CbGeAlD
Lovastatin—Flushing—Epirubicin—thyroid cancer	0.000302	0.0023	CcSEcCtD
Lovastatin—Hepatitis—Doxorubicin—thyroid cancer	0.000301	0.00229	CcSEcCtD
Lovastatin—Chills—Epirubicin—thyroid cancer	0.000292	0.00222	CcSEcCtD
Lovastatin—Alopecia—Epirubicin—thyroid cancer	0.000288	0.00219	CcSEcCtD
Lovastatin—Erythema multiforme—Doxorubicin—thyroid cancer	0.000285	0.00217	CcSEcCtD
Lovastatin—Flushing—Doxorubicin—thyroid cancer	0.00028	0.00213	CcSEcCtD
Lovastatin—Flatulence—Epirubicin—thyroid cancer	0.000279	0.00213	CcSEcCtD
Lovastatin—Dysgeusia—Epirubicin—thyroid cancer	0.000277	0.00211	CcSEcCtD
Lovastatin—Back pain—Epirubicin—thyroid cancer	0.000274	0.00209	CcSEcCtD
Lovastatin—Muscle spasms—Epirubicin—thyroid cancer	0.000272	0.00207	CcSEcCtD
Lovastatin—Chills—Doxorubicin—thyroid cancer	0.00027	0.00206	CcSEcCtD
Lovastatin—Vision blurred—Epirubicin—thyroid cancer	0.000267	0.00203	CcSEcCtD
Lovastatin—Alopecia—Doxorubicin—thyroid cancer	0.000266	0.00203	CcSEcCtD
Lovastatin—Ill-defined disorder—Epirubicin—thyroid cancer	0.000263	0.002	CcSEcCtD
Lovastatin—Flatulence—Doxorubicin—thyroid cancer	0.000258	0.00197	CcSEcCtD
Lovastatin—Dysgeusia—Doxorubicin—thyroid cancer	0.000257	0.00195	CcSEcCtD
Lovastatin—Malaise—Epirubicin—thyroid cancer	0.000256	0.00195	CcSEcCtD
Lovastatin—Vertigo—Epirubicin—thyroid cancer	0.000255	0.00194	CcSEcCtD
Lovastatin—Leukopenia—Epirubicin—thyroid cancer	0.000254	0.00193	CcSEcCtD
Lovastatin—Back pain—Doxorubicin—thyroid cancer	0.000254	0.00193	CcSEcCtD
Lovastatin—Muscle spasms—Doxorubicin—thyroid cancer	0.000252	0.00192	CcSEcCtD
Lovastatin—Vision blurred—Doxorubicin—thyroid cancer	0.000247	0.00188	CcSEcCtD
Lovastatin—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000243	0.00185	CcSEcCtD
Lovastatin—Arthralgia—Epirubicin—thyroid cancer	0.000241	0.00184	CcSEcCtD
Lovastatin—Chest pain—Epirubicin—thyroid cancer	0.000241	0.00184	CcSEcCtD
Lovastatin—Myalgia—Epirubicin—thyroid cancer	0.000241	0.00184	CcSEcCtD
Lovastatin—Anxiety—Epirubicin—thyroid cancer	0.00024	0.00183	CcSEcCtD
Lovastatin—Discomfort—Epirubicin—thyroid cancer	0.000238	0.00181	CcSEcCtD
Lovastatin—Malaise—Doxorubicin—thyroid cancer	0.000236	0.0018	CcSEcCtD
Lovastatin—Dry mouth—Epirubicin—thyroid cancer	0.000236	0.0018	CcSEcCtD
Lovastatin—Vertigo—Doxorubicin—thyroid cancer	0.000236	0.00179	CcSEcCtD
Lovastatin—Leukopenia—Doxorubicin—thyroid cancer	0.000235	0.00179	CcSEcCtD
Lovastatin—Confusional state—Epirubicin—thyroid cancer	0.000233	0.00178	CcSEcCtD
Lovastatin—Anaphylactic shock—Epirubicin—thyroid cancer	0.000231	0.00176	CcSEcCtD
Lovastatin—Infection—Epirubicin—thyroid cancer	0.00023	0.00175	CcSEcCtD
Lovastatin—Thrombocytopenia—Epirubicin—thyroid cancer	0.000226	0.00172	CcSEcCtD
Lovastatin—Arthralgia—Doxorubicin—thyroid cancer	0.000223	0.0017	CcSEcCtD
Lovastatin—Chest pain—Doxorubicin—thyroid cancer	0.000223	0.0017	CcSEcCtD
Lovastatin—Myalgia—Doxorubicin—thyroid cancer	0.000223	0.0017	CcSEcCtD
Lovastatin—Anxiety—Doxorubicin—thyroid cancer	0.000222	0.00169	CcSEcCtD
Lovastatin—Discomfort—Doxorubicin—thyroid cancer	0.000221	0.00168	CcSEcCtD
Lovastatin—Anorexia—Epirubicin—thyroid cancer	0.00022	0.00168	CcSEcCtD
Lovastatin—Dry mouth—Doxorubicin—thyroid cancer	0.000218	0.00166	CcSEcCtD
Lovastatin—Confusional state—Doxorubicin—thyroid cancer	0.000216	0.00164	CcSEcCtD
Lovastatin—ABCB1—lymph node—thyroid cancer	0.000215	0.00408	CbGeAlD
Lovastatin—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000214	0.00163	CcSEcCtD
Lovastatin—Infection—Doxorubicin—thyroid cancer	0.000213	0.00162	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000211	0.0016	CcSEcCtD
Lovastatin—Thrombocytopenia—Doxorubicin—thyroid cancer	0.00021	0.0016	CcSEcCtD
Lovastatin—Insomnia—Epirubicin—thyroid cancer	0.000209	0.00159	CcSEcCtD
Lovastatin—Paraesthesia—Epirubicin—thyroid cancer	0.000208	0.00158	CcSEcCtD
Lovastatin—Dyspnoea—Epirubicin—thyroid cancer	0.000206	0.00157	CcSEcCtD
Lovastatin—Anorexia—Doxorubicin—thyroid cancer	0.000204	0.00155	CcSEcCtD
Lovastatin—Dyspepsia—Epirubicin—thyroid cancer	0.000204	0.00155	CcSEcCtD
Lovastatin—Decreased appetite—Epirubicin—thyroid cancer	0.000201	0.00153	CcSEcCtD
Lovastatin—Fatigue—Epirubicin—thyroid cancer	0.000199	0.00152	CcSEcCtD
Lovastatin—Constipation—Epirubicin—thyroid cancer	0.000198	0.00151	CcSEcCtD
Lovastatin—Pain—Epirubicin—thyroid cancer	0.000198	0.00151	CcSEcCtD
Lovastatin—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000195	0.00148	CcSEcCtD
Lovastatin—Insomnia—Doxorubicin—thyroid cancer	0.000194	0.00147	CcSEcCtD
Lovastatin—Paraesthesia—Doxorubicin—thyroid cancer	0.000192	0.00146	CcSEcCtD
Lovastatin—Dyspnoea—Doxorubicin—thyroid cancer	0.000191	0.00145	CcSEcCtD
Lovastatin—Feeling abnormal—Epirubicin—thyroid cancer	0.000191	0.00145	CcSEcCtD
Lovastatin—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000189	0.00144	CcSEcCtD
Lovastatin—Dyspepsia—Doxorubicin—thyroid cancer	0.000188	0.00143	CcSEcCtD
Lovastatin—Decreased appetite—Doxorubicin—thyroid cancer	0.000186	0.00142	CcSEcCtD
Lovastatin—Fatigue—Doxorubicin—thyroid cancer	0.000184	0.0014	CcSEcCtD
Lovastatin—Urticaria—Epirubicin—thyroid cancer	0.000184	0.0014	CcSEcCtD
Lovastatin—Constipation—Doxorubicin—thyroid cancer	0.000183	0.00139	CcSEcCtD
Lovastatin—Pain—Doxorubicin—thyroid cancer	0.000183	0.00139	CcSEcCtD
Lovastatin—Abdominal pain—Epirubicin—thyroid cancer	0.000183	0.00139	CcSEcCtD
Lovastatin—Body temperature increased—Epirubicin—thyroid cancer	0.000183	0.00139	CcSEcCtD
Lovastatin—Feeling abnormal—Doxorubicin—thyroid cancer	0.000176	0.00134	CcSEcCtD
Lovastatin—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000175	0.00133	CcSEcCtD
Lovastatin—Hypersensitivity—Epirubicin—thyroid cancer	0.00017	0.0013	CcSEcCtD
Lovastatin—Urticaria—Doxorubicin—thyroid cancer	0.00017	0.00129	CcSEcCtD
Lovastatin—Body temperature increased—Doxorubicin—thyroid cancer	0.000169	0.00129	CcSEcCtD
Lovastatin—Abdominal pain—Doxorubicin—thyroid cancer	0.000169	0.00129	CcSEcCtD
Lovastatin—Asthenia—Epirubicin—thyroid cancer	0.000166	0.00126	CcSEcCtD
Lovastatin—Pruritus—Epirubicin—thyroid cancer	0.000164	0.00125	CcSEcCtD
Lovastatin—Diarrhoea—Epirubicin—thyroid cancer	0.000158	0.0012	CcSEcCtD
Lovastatin—Hypersensitivity—Doxorubicin—thyroid cancer	0.000158	0.0012	CcSEcCtD
Lovastatin—Asthenia—Doxorubicin—thyroid cancer	0.000154	0.00117	CcSEcCtD
Lovastatin—Dizziness—Epirubicin—thyroid cancer	0.000153	0.00116	CcSEcCtD
Lovastatin—Pruritus—Doxorubicin—thyroid cancer	0.000151	0.00115	CcSEcCtD
Lovastatin—Vomiting—Epirubicin—thyroid cancer	0.000147	0.00112	CcSEcCtD
Lovastatin—Diarrhoea—Doxorubicin—thyroid cancer	0.000146	0.00111	CcSEcCtD
Lovastatin—Rash—Epirubicin—thyroid cancer	0.000146	0.00111	CcSEcCtD
Lovastatin—Dermatitis—Epirubicin—thyroid cancer	0.000146	0.00111	CcSEcCtD
Lovastatin—Headache—Epirubicin—thyroid cancer	0.000145	0.0011	CcSEcCtD
Lovastatin—Dizziness—Doxorubicin—thyroid cancer	0.000141	0.00108	CcSEcCtD
Lovastatin—Nausea—Epirubicin—thyroid cancer	0.000137	0.00105	CcSEcCtD
Lovastatin—Vomiting—Doxorubicin—thyroid cancer	0.000136	0.00104	CcSEcCtD
Lovastatin—Rash—Doxorubicin—thyroid cancer	0.000135	0.00103	CcSEcCtD
Lovastatin—Dermatitis—Doxorubicin—thyroid cancer	0.000135	0.00103	CcSEcCtD
Lovastatin—Headache—Doxorubicin—thyroid cancer	0.000134	0.00102	CcSEcCtD
Lovastatin—Nausea—Doxorubicin—thyroid cancer	0.000127	0.000968	CcSEcCtD
Lovastatin—HDAC2—Direct p53 effectors—TP53—thyroid cancer	7.96e-05	0.0012	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—CHST14—thyroid cancer	7.95e-05	0.0012	CbGpPWpGaD
Lovastatin—HMGCR—Integrated Breast Cancer Pathway—AKT1—thyroid cancer	7.91e-05	0.00119	CbGpPWpGaD
Lovastatin—ITGAL—Hemostasis—AKT1—thyroid cancer	7.82e-05	0.00118	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—TPR—thyroid cancer	7.77e-05	0.00117	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—HRAS—thyroid cancer	7.66e-05	0.00116	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PRKAR1A—thyroid cancer	7.64e-05	0.00115	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—HPGD—thyroid cancer	7.62e-05	0.00115	CbGpPWpGaD
Lovastatin—CYP2C19—Biological oxidations—RXRA—thyroid cancer	7.56e-05	0.00114	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—MEN1—thyroid cancer	7.51e-05	0.00113	CbGpPWpGaD
Lovastatin—SLCO1A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	7.49e-05	0.00113	CbGpPWpGaD
Lovastatin—HDAC2—Disease—TPR—thyroid cancer	7.41e-05	0.00112	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	7.33e-05	0.00111	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PRKAR1A—thyroid cancer	7.29e-05	0.0011	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—MINPP1—thyroid cancer	7.19e-05	0.00108	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—PTEN—thyroid cancer	7.12e-05	0.00107	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TCF7L1—thyroid cancer	7.09e-05	0.00107	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—HPGD—thyroid cancer	6.98e-05	0.00105	CbGpPWpGaD
Lovastatin—HDAC2—Disease—MEN1—thyroid cancer	6.97e-05	0.00105	CbGpPWpGaD
Lovastatin—CYP2D6—Biological oxidations—RXRA—thyroid cancer	6.96e-05	0.00105	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.93e-05	0.00105	CbGpPWpGaD
Lovastatin—CYP2C9—Biological oxidations—RXRA—thyroid cancer	6.9e-05	0.00104	CbGpPWpGaD
Lovastatin—ABCC2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	6.82e-05	0.00103	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	6.79e-05	0.00102	CbGpPWpGaD
Lovastatin—ITGAL—Adaptive Immune System—AKT1—thyroid cancer	6.76e-05	0.00102	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.62e-05	0.000999	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—PTEN—thyroid cancer	6.59e-05	0.000994	CbGpPWpGaD
Lovastatin—SLCO1B1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	6.41e-05	0.000967	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—HPGD—thyroid cancer	6.41e-05	0.000967	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—NRAS—thyroid cancer	6.35e-05	0.000959	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—TPR—thyroid cancer	6.33e-05	0.000956	CbGpPWpGaD
Lovastatin—SLCO1A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	6.3e-05	0.00095	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PRKAR1A—thyroid cancer	6.23e-05	0.00094	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—MINPP1—thyroid cancer	6.22e-05	0.00094	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—NDUFA13—thyroid cancer	6.11e-05	0.000922	CbGpPWpGaD
Lovastatin—HDAC2—Circadian rythm related genes—TP53—thyroid cancer	5.96e-05	0.0009	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—NRAS—thyroid cancer	5.88e-05	0.000887	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—SLC5A5—thyroid cancer	5.81e-05	0.000878	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—CHST14—thyroid cancer	5.74e-05	0.000867	CbGpPWpGaD
Lovastatin—ABCC2—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.73e-05	0.000865	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.66e-05	0.000855	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—MINPP1—thyroid cancer	5.56e-05	0.000839	CbGpPWpGaD
Lovastatin—HDAC2—Disease—CALCA—thyroid cancer	5.55e-05	0.000838	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—KRAS—thyroid cancer	5.47e-05	0.000825	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.45e-05	0.000822	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—MINPP1—thyroid cancer	5.42e-05	0.000819	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—TPR—thyroid cancer	5.38e-05	0.000813	CbGpPWpGaD
Lovastatin—SLCO1B1—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.38e-05	0.000813	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PRKAR1A—thyroid cancer	5.3e-05	0.0008	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—NDUFA13—thyroid cancer	5.29e-05	0.000799	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TSHR—thyroid cancer	5.19e-05	0.000784	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—MINPP1—thyroid cancer	5.11e-05	0.000771	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PRKAR1A—thyroid cancer	5.11e-05	0.000771	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—MINPP1—thyroid cancer	5.07e-05	0.000765	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—KRAS—thyroid cancer	5.06e-05	0.000763	CbGpPWpGaD
Lovastatin—HDAC2—Disease—CDK1—thyroid cancer	5.02e-05	0.000758	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—RXRA—thyroid cancer	5.02e-05	0.000758	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—CHST14—thyroid cancer	4.98e-05	0.000751	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—RXRA—thyroid cancer	4.89e-05	0.000737	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—MEN1—thyroid cancer	4.88e-05	0.000737	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.75e-05	0.000717	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—SLC5A5—thyroid cancer	4.74e-05	0.000715	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—NDUFA13—thyroid cancer	4.72e-05	0.000713	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—TPR—thyroid cancer	4.69e-05	0.000708	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—HRAS—thyroid cancer	4.65e-05	0.000701	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—HPGD—thyroid cancer	4.63e-05	0.000699	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PRKAR1A—thyroid cancer	4.61e-05	0.000696	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—NDUFA13—thyroid cancer	4.61e-05	0.000696	CbGpPWpGaD
Lovastatin—CYP3A4—Biological oxidations—RXRA—thyroid cancer	4.55e-05	0.000686	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—CHST14—thyroid cancer	4.44e-05	0.00067	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PTCH1—thyroid cancer	4.41e-05	0.000666	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—TPR—thyroid cancer	4.37e-05	0.00066	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—NDUFA13—thyroid cancer	4.34e-05	0.000656	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—CHST14—thyroid cancer	4.34e-05	0.000654	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—NDUFA13—thyroid cancer	4.31e-05	0.00065	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PRKAR1A—thyroid cancer	4.3e-05	0.00065	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—HRAS—thyroid cancer	4.3e-05	0.000649	CbGpPWpGaD
Lovastatin—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	4.28e-05	0.000647	CbGpPWpGaD
Lovastatin—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	4.28e-05	0.000647	CbGpPWpGaD
Lovastatin—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	4.22e-05	0.000636	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.18e-05	0.000631	CbGpPWpGaD
Lovastatin—ITGAL—Immune System—AKT1—thyroid cancer	4.1e-05	0.000619	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—CHST14—thyroid cancer	4.09e-05	0.000617	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—CHST14—thyroid cancer	4.05e-05	0.000611	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—SST—thyroid cancer	4.04e-05	0.00061	CbGpPWpGaD
Lovastatin—HDAC2—Disease—NRG1—thyroid cancer	4.03e-05	0.000609	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—SLC5A5—thyroid cancer	4.03e-05	0.000608	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—HPGD—thyroid cancer	4.01e-05	0.000605	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—TPR—thyroid cancer	4.01e-05	0.000605	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—RXRA—thyroid cancer	3.98e-05	0.000601	CbGpPWpGaD
Lovastatin—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	3.96e-05	0.000598	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PRKAR1A—thyroid cancer	3.94e-05	0.000595	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CALCA—thyroid cancer	3.89e-05	0.000587	CbGpPWpGaD
Lovastatin—HDAC2—Signaling by NGF—AKT1—thyroid cancer	3.8e-05	0.000573	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—NRAS—thyroid cancer	3.72e-05	0.000562	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—TPR—thyroid cancer	3.68e-05	0.000555	CbGpPWpGaD
Lovastatin—HDAC2—Disease—TERT—thyroid cancer	3.62e-05	0.000547	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PRKAR1A—thyroid cancer	3.62e-05	0.000546	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—HPGD—thyroid cancer	3.58e-05	0.00054	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.57e-05	0.00054	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CDK1—thyroid cancer	3.52e-05	0.000531	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—SLC5A5—thyroid cancer	3.51e-05	0.00053	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—HPGD—thyroid cancer	3.49e-05	0.000527	CbGpPWpGaD
Lovastatin—HDAC2—Disease—HIF1A—thyroid cancer	3.46e-05	0.000523	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—RXRA—thyroid cancer	3.39e-05	0.000511	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	3.37e-05	0.000509	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—MINPP1—thyroid cancer	3.34e-05	0.000504	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—HPGD—thyroid cancer	3.29e-05	0.000497	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.29e-05	0.000496	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—SLC5A5—thyroid cancer	3.28e-05	0.000494	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—HPGD—thyroid cancer	3.26e-05	0.000493	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.25e-05	0.000491	CbGpPWpGaD
Lovastatin—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	3.21e-05	0.000484	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—KRAS—thyroid cancer	3.2e-05	0.000484	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—PPARG—thyroid cancer	3.17e-05	0.000479	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PPARG—thyroid cancer	3.08e-05	0.000466	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	3.05e-05	0.00046	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—SLC5A5—thyroid cancer	3e-05	0.000453	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—RXRA—thyroid cancer	2.95e-05	0.000445	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	2.94e-05	0.000444	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.9e-05	0.000438	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.87e-05	0.000433	CbGpPWpGaD
Lovastatin—HDAC2—Disease—BRAF—thyroid cancer	2.87e-05	0.000433	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—TP53—thyroid cancer	2.85e-05	0.00043	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—NDUFA13—thyroid cancer	2.84e-05	0.000429	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—NRG1—thyroid cancer	2.82e-05	0.000426	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.81e-05	0.000424	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—SLC5A5—thyroid cancer	2.75e-05	0.000416	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—RXRA—thyroid cancer	2.75e-05	0.000415	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—HRAS—thyroid cancer	2.72e-05	0.000411	CbGpPWpGaD
Lovastatin—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	2.7e-05	0.000407	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—CHST14—thyroid cancer	2.67e-05	0.000403	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—TPR—thyroid cancer	2.66e-05	0.000401	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.65e-05	0.0004	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	2.62e-05	0.000395	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TERT—thyroid cancer	2.54e-05	0.000383	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—RXRA—thyroid cancer	2.52e-05	0.000381	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PPARG—thyroid cancer	2.51e-05	0.00038	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.45e-05	0.00037	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PTGS2—thyroid cancer	2.43e-05	0.000366	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—HIF1A—thyroid cancer	2.42e-05	0.000366	CbGpPWpGaD
Lovastatin—HDAC2—Hemostasis—AKT1—thyroid cancer	2.4e-05	0.000363	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PTGS2—thyroid cancer	2.32e-05	0.00035	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—RXRA—thyroid cancer	2.31e-05	0.000349	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—TPR—thyroid cancer	2.3e-05	0.000348	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	2.27e-05	0.000342	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	2.26e-05	0.000341	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—HPGD—thyroid cancer	2.15e-05	0.000325	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PPARG—thyroid cancer	2.14e-05	0.000323	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—PTEN—thyroid cancer	2.12e-05	0.000319	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—TPR—thyroid cancer	2.06e-05	0.00031	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.05e-05	0.00031	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	2.02e-05	0.000305	CbGpPWpGaD
Lovastatin—HDAC2—Disease—PTEN—thyroid cancer	2.02e-05	0.000305	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—BRAF—thyroid cancer	2.01e-05	0.000303	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—TPR—thyroid cancer	2.01e-05	0.000303	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	2.01e-05	0.000303	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—SLC5A5—thyroid cancer	1.99e-05	0.000301	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PTGS2—thyroid cancer	1.98e-05	0.000299	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PRKAR1A—thyroid cancer	1.97e-05	0.000298	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—TPR—thyroid cancer	1.89e-05	0.000285	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—TPR—thyroid cancer	1.87e-05	0.000283	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PPARG—thyroid cancer	1.86e-05	0.000281	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	1.86e-05	0.000281	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	1.84e-05	0.000278	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.83e-05	0.000277	CbGpPWpGaD
Lovastatin—HDAC2—Disease—NRAS—thyroid cancer	1.8e-05	0.000272	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PPARG—thyroid cancer	1.74e-05	0.000262	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—PTEN—thyroid cancer	1.73e-05	0.00026	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—SLC5A5—thyroid cancer	1.72e-05	0.00026	CbGpPWpGaD
Lovastatin—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	1.69e-05	0.000256	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PTGS2—thyroid cancer	1.68e-05	0.000254	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—RXRA—thyroid cancer	1.67e-05	0.000253	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.67e-05	0.000252	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.62e-05	0.000244	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PPARG—thyroid cancer	1.59e-05	0.00024	CbGpPWpGaD
Lovastatin—HDAC2—Disease—KRAS—thyroid cancer	1.55e-05	0.000234	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—SLC5A5—thyroid cancer	1.54e-05	0.000232	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—SLC5A5—thyroid cancer	1.5e-05	0.000227	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—PTEN—thyroid cancer	1.47e-05	0.000221	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—CCND1—thyroid cancer	1.47e-05	0.000221	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PTGS2—thyroid cancer	1.46e-05	0.000221	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PPARG—thyroid cancer	1.46e-05	0.000221	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—RXRA—thyroid cancer	1.45e-05	0.000219	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.44e-05	0.000218	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—SLC5A5—thyroid cancer	1.42e-05	0.000214	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—PTEN—thyroid cancer	1.41e-05	0.000214	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.41e-05	0.000213	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.4e-05	0.000212	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PTGS2—thyroid cancer	1.37e-05	0.000206	CbGpPWpGaD
Lovastatin—HDAC2—Disease—HRAS—thyroid cancer	1.32e-05	0.000199	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.32e-05	0.000199	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—RXRA—thyroid cancer	1.29e-05	0.000195	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—PTEN—thyroid cancer	1.28e-05	0.000193	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—RXRA—thyroid cancer	1.26e-05	0.000191	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—NRAS—thyroid cancer	1.26e-05	0.000191	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.26e-05	0.00019	CbGpPWpGaD
Lovastatin—HDAC2—Gene Expression—AKT1—thyroid cancer	1.25e-05	0.000189	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PTGS2—thyroid cancer	1.25e-05	0.000189	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—TPR—thyroid cancer	1.24e-05	0.000187	CbGpPWpGaD
Lovastatin—HMGCR—Metabolism—AKT1—thyroid cancer	1.22e-05	0.000184	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	1.22e-05	0.000184	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—PTEN—thyroid cancer	1.19e-05	0.00018	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—RXRA—thyroid cancer	1.19e-05	0.00018	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—RXRA—thyroid cancer	1.18e-05	0.000178	CbGpPWpGaD
Lovastatin—HDAC2—Disease—AKT1—thyroid cancer	1.16e-05	0.000176	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PTGS2—thyroid cancer	1.15e-05	0.000174	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.15e-05	0.000173	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—PTEN—thyroid cancer	1.09e-05	0.000165	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—KRAS—thyroid cancer	1.09e-05	0.000164	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PPARG—thyroid cancer	1.06e-05	0.000159	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—PTEN—thyroid cancer	1e-05	0.000151	CbGpPWpGaD
Lovastatin—UGT1A3—Metabolism—AKT1—thyroid cancer	9.94e-06	0.00015	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—TP53—thyroid cancer	9.65e-06	0.000146	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—SLC5A5—thyroid cancer	9.26e-06	0.00014	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—HRAS—thyroid cancer	9.23e-06	0.000139	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PPARG—thyroid cancer	9.15e-06	0.000138	CbGpPWpGaD
Lovastatin—UGT2B7—Metabolism—AKT1—thyroid cancer	8.45e-06	0.000128	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PTGS2—thyroid cancer	8.31e-06	0.000125	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PPARG—thyroid cancer	8.17e-06	0.000123	CbGpPWpGaD
Lovastatin—HDAC2—Signaling Pathways—AKT1—thyroid cancer	8.15e-06	0.000123	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PPARG—thyroid cancer	7.97e-06	0.00012	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—RXRA—thyroid cancer	7.78e-06	0.000117	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PPARG—thyroid cancer	7.51e-06	0.000113	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PPARG—thyroid cancer	7.45e-06	0.000112	CbGpPWpGaD
Lovastatin—SLCO1A2—Metabolism—AKT1—thyroid cancer	7.36e-06	0.000111	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—PTEN—thyroid cancer	7.25e-06	0.000109	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PTGS2—thyroid cancer	7.2e-06	0.000109	CbGpPWpGaD
Lovastatin—UGT1A1—Metabolism—AKT1—thyroid cancer	6.87e-06	0.000104	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PTGS2—thyroid cancer	6.42e-06	9.7e-05	CbGpPWpGaD
Lovastatin—SLCO1B1—Metabolism—AKT1—thyroid cancer	6.29e-06	9.5e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—PTEN—thyroid cancer	6.28e-06	9.47e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PTGS2—thyroid cancer	6.27e-06	9.46e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PTGS2—thyroid cancer	5.91e-06	8.92e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PTGS2—thyroid cancer	5.86e-06	8.84e-05	CbGpPWpGaD
Lovastatin—CYP3A7—Metabolism—AKT1—thyroid cancer	5.78e-06	8.72e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—PTEN—thyroid cancer	5.6e-06	8.46e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—PTEN—thyroid cancer	5.47e-06	8.25e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—PTEN—thyroid cancer	5.15e-06	7.78e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—PTEN—thyroid cancer	5.11e-06	7.71e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PPARG—thyroid cancer	4.91e-06	7.41e-05	CbGpPWpGaD
Lovastatin—CYP3A5—Metabolism—AKT1—thyroid cancer	4.18e-06	6.3e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PTGS2—thyroid cancer	3.86e-06	5.83e-05	CbGpPWpGaD
Lovastatin—CYP2C8—Metabolism—AKT1—thyroid cancer	3.62e-06	5.46e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—PTEN—thyroid cancer	3.37e-06	5.09e-05	CbGpPWpGaD
Lovastatin—CYP2C19—Metabolism—AKT1—thyroid cancer	3.23e-06	4.87e-05	CbGpPWpGaD
Lovastatin—ABCB1—Metabolism—AKT1—thyroid cancer	3.15e-06	4.76e-05	CbGpPWpGaD
Lovastatin—CYP2D6—Metabolism—AKT1—thyroid cancer	2.97e-06	4.48e-05	CbGpPWpGaD
Lovastatin—CYP2C9—Metabolism—AKT1—thyroid cancer	2.94e-06	4.44e-05	CbGpPWpGaD
Lovastatin—CYP3A4—Metabolism—AKT1—thyroid cancer	1.94e-06	2.93e-05	CbGpPWpGaD
